Skip to main
HOTH
HOTH logo

Hoth Therapeutics (HOTH) Stock Forecast & Price Target

Hoth Therapeutics (HOTH) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Hoth Therapeutics Inc. is demonstrating a positive outlook due to its focused development of innovative therapies that address significant unmet medical needs, particularly in oncology and metabolic diseases. The company has recorded over 65% of participants in their clinical trials reporting reductions in pain and pruritus, indicating considerable progress in symptom improvement for patients. Additionally, Hoth's second quarter 2025 results highlighted disciplined expense management while advancing its lead asset, HT-001, into a broader development phase, suggesting a strong commitment to growth and operational efficiency.

Bears say

Hoth Therapeutics Inc reported no revenues for the second quarter of 2025, consistent with expectations, while total operating expenses decreased to $2.2 million from $3.4 million in the previous quarter. The company incurred a net loss of $2.2 million, translating to a loss of $(0.17) per share. This financial performance highlights ongoing operational challenges and raises concerns about the company's ability to generate revenue in the near term, contributing to a negative outlook on its stock.

Hoth Therapeutics (HOTH) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Hoth Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Hoth Therapeutics (HOTH) Forecast

Analysts have given Hoth Therapeutics (HOTH) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Hoth Therapeutics (HOTH) has a Strong Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Hoth Therapeutics (HOTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.